# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst Christopher Raymond maintains AbbVie (NYSE:ABBV) with a Overweight and maintains $190 price target.
As Previously Announced, Richard A. Gonzalez Retires as Chief Executive Officer to Become Executive ChairmanRobert A. Michael J...
AbbVie (NYSE:ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Us...
The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractor...
Celsius' CEL383 is a potential first-in-class anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody for th...